摘要
目的:探讨阿奇霉素序贯治疗小儿支原体肺炎的临床疗效。方法:采用随机对照分组研究方法,将80例患儿随机分为两组,阿奇霉素序贯治疗组40例,红霉素治疗组40例,比较两组的疗效及不良反应。结果:治疗组治愈率和总有效率分别为65.0%、95.0%,对照组治愈率和总有效率分别为47.5%、75.0%,治疗组优于对照组,但两组比较差异无统计学意义(P>0.05)。治疗组退热时间、咳嗽好转时间、啰音消失时间及平均住院时间均较对照组缩短(P<0.01),而且局部疼痛、胃肠道反应及肝功损伤程度明显降低(P<0.05)。结论:阿奇霉素序贯治疗小儿支原体肺炎优于红霉素,具有起效快、疗效好、安全性高、不良反应少等优点,值得临床推广。
Objective： To evaluate the clinic curative effect of azithromycin sequential therapy on mycoplasmal pneumonia （MP） in children. Methods： We divided 80 MP children into azithromycin group （40 cases） and erythromycin group （40 cases） randomly, with their curative effects and adverse reactions compared. Results： The rates of healing and general efficiency for azithromycin group were 65.0% and 95.0% while 47.5% and 75.0% in the erythromyein group, and there was no difference between the two groups （ P 〉 0.05 ）. Time of pyretolysis, cough relief, hello lung sound disappearing and the mean length of hospitalization of the azithromycin sequential therapy group were shorter than those of the erythromyein group （P 〈 0. 01 ）. The local ache, stomach and intestinal tract adverse reaction, and damage of hepar function were less than those in the erytkromycin group（P 〈 0.05 ）. Conclusions： Azithromycin sequential therapy is better than erythromycin for MP children with a quicker and better effect, better safety and fewer adverse reaction etc. and worth promoting.
出处
《儿科药学杂志》
CAS
2009年第2期18-19,21,共3页
Journal of Pediatric Pharmacy
关键词
阿奇霉素
红霉素
肺炎
支原体
Azithromycin
Erythromycin
Pneumonia
Mycoplasmal
